Insight

The journey of ADCs is a story of perseverance

Raffaele Colombo/LinkedIn

Nov 7, 2024, 16:03

The journey of ADCs is a story of perseverance

An article by Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks Inc., was recently mentioned by Fabrice Dunand, Senior Director of GSI and Global Head of Early-Stage Oncology at GSK, on LinkedIn:

“The journey of Antibody-Drug Conjugates is a story of perseverance.

‘The approval pace of oncology-directed ADCs clearly demonstrates that this technology is experiencing an unprecedented expansion. It took about 20 years of research for the first ADC approval in 2000 and has taken more than 10 additional years before a second approval.

By contrast, eight novel ADCs were approved within only the last 5 years and the first agnostic approval has just been granted to an ADC’.”

“The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development”

Authors: Raffaele Colombo, Paolo Tarantino, Jamie Rich, Patricia LoRusso, Elisabeth de Vries.

The journey of ADCs is a story of perseverance

More posts featuring Raffaele Colombo.

Fabrice Dunand is Senior Director of GSI and Global Head of Early-Stage Oncology at GSK. He is an expert in strategic planning and insights, focusing on developing business plans, strategic marketing, and commercial strategies for innovative therapies, including gene and cell therapies and microbiome-based treatments, across multiple fields such as oncology, gastroenterology, urology, reproductive medicine, maternal health, and infectious diseases.

Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.